# SAMETA (NCT05043090)

> Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05043090
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Papillary Renal Cell Carcinoma
- Interventions: savolitinib; durvalumab; sunitinib
- Enrollment: 148
- Primary outcome: Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib

## Commentary we found

- X threads: 29
- YouTube: 10
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sameta-nct05043090

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05043090", "email": "<work email>"}; the inbox owner confirms by the emailed link.